-
Hillstream BioPharma to Present at BioNJ’s 12th Annual BioPartnering Virtual Conference Held on May 9- 13, 2022
Hillstream BioPharma to Present at BioNJ's 12th Annual BioPartnering Virtual Conference Held on May 9- 13, 2022 March 6th, 2022 Developed in partnership with J.P. Morgan and Johnson & Johnson Innovation, the…May 6, 2022 -
Hillstream BioPharma R&D Day Highlights Ferroptosis, the Non-Genetic Novel, Emerging Mechanism of Action, Targeting Drug Resistant and Devastating Cancers
Hillstream BioPharma Announces Acceptance of Abstract at AACR 2022 Annual Meeting Highlighting HSB-510, a Novel Quatramer-based, First-in-Class Dual Inhibitor of HDAC6 and PI3K-delta Downregulating c-myc Expression March 2nd, 2022 HSB-1216’s active moiety…March 2, 2022 -
February 24, 2022 Hillstream R & D Day 8:00 AM – Targeting Ferroptosis to Iron Out Resistant Cancers
Please join us on R & D Day 8:00 AM - Targeting Ferroptosis to Iron Out Resistant CancersFebruary 22, 2022 -
Hillstream BioPharma Receives Orphan Drug Designation for HSB-1216 for the Treatment of Uveal Melanoma
Hillstream BioPharma Receives Orphan Drug Designation for HSB-1216 for the Treatment of Uveal Melanoma February 16th, 2022 -Uveal melanoma is an aggressive intraocular malignancy with a poor prognosis in which 50% of…February 16, 2022 -
Hillstream BioPharma Provides Business Review with Key Pipeline Updates
Hillstream BioPharma Provides Business Review with Key Pipeline Updates February 14th, 2022 Continued development and validation of HSB-1216 as a leading Ferroptosis inducer to enter the clinic Successful Closing of a $15…February 14, 2022 -
SAVE THE DATES: Hillstream BioPharma Announces R&D Day on February 24, 2022 and Business Review on Monday February 14, 2022
SAVE THE DATES: Hillstream BioPharma Announces R&D Day on February 24, 2022 and Business Review on Monday February 14, 2022 February 11th, 2022 R&D Day on Thursday February 24, 2022 at 8:00…February 11, 2022 -
Hillstream BioPharma Announces Acceptance of Abstract at AACR 2022 Annual Meeting Highlighting HSB-510, a Novel Quatramer-based, First-in-Class Dual Inhibitor of HDAC6 and PI3K-delta Downregulating c-myc Expression
Hillstream BioPharma Announces Acceptance of Abstract at AACR 2022 Annual Meeting Highlighting HSB-510, a Novel Quatramer-based, First-in-Class Dual Inhibitor of HDAC6 and PI3K-delta Downregulating c-myc Expression February 1st, 2022 Bridgewater, NJ –…February 1, 2022 -
Hillstream BioPharma and University of Massachusetts Chan Medical School Announce Research Collaboration using CRISPR and Computational Approaches to Advance The Hillstream Ferroptomic Atlas
Hillstream BioPharma and University of Massachusetts Chan Medical School Announce Research Collaboration using CRISPR and Computational Approaches to Advance The Hillstream Ferroptomic Atlas January 26th, 2022 Collaboration Aims to Identify Novel Chemogenetic…January 26, 2022 -
Hillstream BioPharma Announces Closing of Initial Public Offering
Hillstream BioPharma Announces Closing of Initial Public Offering January 14th, 2022 Bridgewater, NJ (January 14, 2022) – Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream”, the “Company”), a biotechnology company developing novel therapeutic candidates targeting ferroptosis,…January 14, 2022 -
Hillstream BioPharma Announces Pricing of Initial Public Offering
Hillstream BioPharma Announces Pricing of Initial Public Offering January 11th, 2022 BRIDGEWATER, NJ / ACCESSWIRE / January 11, 2022 / Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream", the "Company"), a biotechnology company developing novel therapeutic…January 11, 2022
Loading posts...
Recent Posts
- Hillstream BioPharma to Present at BioNJ’s 12th Annual BioPartnering Virtual Conference Held on May 9- 13, 2022
- Hillstream BioPharma R&D Day Highlights Ferroptosis, the Non-Genetic Novel, Emerging Mechanism of Action, Targeting Drug Resistant and Devastating Cancers
- February 24, 2022 Hillstream R & D Day 8:00 AM – Targeting Ferroptosis to Iron Out Resistant Cancers
- Hillstream BioPharma Receives Orphan Drug Designation for HSB-1216 for the Treatment of Uveal Melanoma
- Hillstream BioPharma Provides Business Review with Key Pipeline Updates